Canada's Enobia Pharma has been testing a new drug designed to fight hypophosphatasia, a rare genetic disease that causes bone disorders in adults and rickets in children. Researchers say the disease only occurs in one out of every 100,000 people and is most prevalent in the Mennonite community in Manitoba. Enobia is conducting the trial at three sites around the world. One of those sites is Winnipeg's Health Sciences Centre, where a 10-month-old patient from Northern Ireland is being treated. The child, Amy Tinsley, is reportedly responding well so far.
- read the story from the Winnipeg Free Press